Efficacy and safety of mesenchymal stem cells in the treatment of perianal fistulas in Crohn's disease: a meta-analysis of randomized controlled trials
Revista Española de Enfermedades Digestivas · 2023
DOI: 10.17235/reed.2023.9213/2022 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Revista Española de Enfermedades Digestivas, 2023. Verfasst von Fang Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Zigong First People's Hospital, China. Hauptthemen laut MEDLINE: Crohn Disease, Mesenchymal Stem Cell Transplantation, Rectal Fistula. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Local mesenchymal stem cell (MSC) therapy for perianal fistulas in Crohn's disease (CD) has yielded promising results, but it still remains controversial. In this study, we aimed to conduct a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of MSC therapy for perianal CD (pCD). METHODS: RCTs reporting MSC therapy for perianal fistulas in CD were searched and included. The effectiveness and safety data were analyzed using RevMan 5.3. RESULTS: A total of 7 RCTs were included in this meta-analysis. The analysis showed that patients receiving MSC therapy presented a higher healing rate (HR) of pCD than those in the control group (odds ratio (OR)=1.42; 95% confidence interval (CI) 1.18, 1.71; P=0.0002). Compared with placebo (saline solution), MSC therapy improved the HR of pCD (OR=1.85; 95% CI 1.32, 2.60; P=0.0004). MSC therapy showed significant long-term efficacy (OR=1.36; P=0.009; 95% CI 1.08, 1.71). When MRI was used to evaluate fistula healing, a pooled analysis showed that the MSC group achieved a higher HR than the control group (OR=1.95; 95% CI 1.33, 2.87; P=0.0007). Allogeneic MSC therapy was superior to the control treatment in improving HR (OR = 1.97; 95% CI 1.40, 2.75; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gastroenterology, Zigong First People's Hospital, China.
- Gastroenterology, Zigong First People's Hospital.
ORCID-Profile: Zhong Huang, Wei Wei, Zhi Li
Zitieren
APA
Cheng, F., Huang, Z., Wei, W., & Li, Z. (2023). Efficacy and safety of mesenchymal stem cells in the treatment of perianal fistulas in Crohn's disease: a meta-analysis of randomized controlled trials. Revista Española de Enfermedades Digestivas. https://doi.org/10.17235/reed.2023.9213/2022
Vancouver
Cheng F, Huang Z, Wei W, Li Z. Efficacy and safety of mesenchymal stem cells in the treatment of perianal fistulas in Crohn's disease: a meta-analysis of randomized controlled trials. Revista Española de Enfermedades Digestivas. 2023. doi:10.17235/reed.2023.9213/2022
BibTeX
@article{Cheng2023,
author = {Cheng, Fang and Huang, Zhong and Wei, Wei and Li, Zhi},
title = {Efficacy and safety of mesenchymal stem cells in the treatment of perianal fistulas in Crohn's disease: a meta-analysis of randomized controlled trials},
journal = {Revista Española de Enfermedades Digestivas},
year = {2023},
doi = {10.17235/reed.2023.9213/2022}
}
EUVIMED